Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1531-1538

  Bartlett, John M S ^{a,b,c,d,e,f,g,h,i,j}   Brookes, Cassandra L ^{a,b,c,d,e,f,g,h,i}   Robson, Tammy ^{a,b,c,d,e,f,g,h,i}   Van De Velde, Cornelis J H ^{a,b,c,d,e,f,g,h,i}   Billingham, Lucinda J ^{a,b,c,d,e,f,g,h,i}   Campbell, Fiona M ^{a,b,c,d,e,f,g,h,i}   Grant, Margaret ^{a,b,c,d,e,f,g,h,i}   Hasenburg, Annette ^{a,b,c,d,e,f,g,h,i}   Hille, Elysée T M ^{a,b,c,d,e,f,g,h,i}   Kay, Charlene ^{a,b,c,d,e,f,g,h,i}   Kieback, Dirk G ^{a,b,c,d,e,f,g,h,i}   Putter, Hein ^{a,b,c,d,e,f,g,h,i}   Markopoulos, Christos ^{a,b,c,d,e,f,g,h,i}   Kranenbarg, Elma Meershoek Klein ^{a,b,c,d,e,f,g,h,i}   Mallon, Elizabeth A ^{a,b,c,d,e,f,g,h,i}   Dirix, Luc ^{a,b,c,d,e,f,g,h,i}   Seynaeve, Caroline ^{a,b,c,d,e,f,g,h,i}   Rea, Daniel ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF FREIBURG   (Germany)

^g HELIOS Medical Center   (Germany)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ SINT AUGUSTINUS HOSPITAL   (Belgium)

^j WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TISSUE MICROARRAY; TREATMENT RESPONSE;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955033397     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3677     Document Type: Article

References (33)

1. Tamoxifen for early breast cancer: An overview of the randomised trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
2. Berstein LM, Wang JP, Zheng H, et al: Longterm exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res 10:1530-1534, 2004 (Pubitemid 38365249)
3. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001 (Pubitemid 32492809)
4. Schiff R, Massarweh S, Shou J, et al: Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9:447S-454S, 2003 (Pubitemid 36105786)
5. Witton CJ, Reeves JR, Going JJ, et al: Coexpression of EGFr, HER2, HER3, and HER4 in primary human breast carcinoma. Presented at the 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-13, 2001 (abstr 32)
6. Witton CJ, Reeves JR, Going JJ, et al: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297, 2003 (Pubitemid 36827302)
7. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833, 2008 (Pubitemid 351206760)
8. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995
9. Kirkegaard T, McGlynn LM, Campbell FM, et al: Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifentreated breast cancer patients. Clin Cancer Res 13:1405-1411, 2007 (Pubitemid 46450429)
10. Tovey S, Dunne B, Witton CJ, et al: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11:4835-4842, 2005 (Pubitemid 41557203)
11. Gross GE, Clark GM, Chamness GC, et al: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44:836-840, 1984 (Pubitemid 14184626)
12. Johnston SR: Combinations of endocrine and biological agents: Present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s- 899s, 2005 (Pubitemid 40111102)
13. Miller WR, Bartlett JM, Canney P, et al: Hormonal therapy for postmenopausal breast cancer: The science of sequencing. Breast Cancer Res Treat 103:149-160, 2007 (Pubitemid 46789136)
14. Spears M, Kenicer J, Munro AF, et al: Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. Biomark Med 2:397-407, 2008
15. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
16. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
17. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 23:7512-7517, 2005 (Pubitemid 46291814)
18. Jones SE, Seynaeve C, Hasenburg A, et al: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 15)
19. Faratian D, Kay C, Campbell F, et al: Automated image analysis for high-throughput quantitative detection of ER and PgR expression levels in large-scale clinical studies: The TEAM trial experience. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
20. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005 (Pubitemid 47050838)
21. Collett D: Modelling Survival Data in Medical Research. London, United Kingdom, Chapman & Hall, 1994
22. Altman DG, Andersen PK: Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492-1495, 1999
23. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
24. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
25. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005 (Pubitemid 43016814)
26. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852, 2007 (Pubitemid 47477259)
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
28. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
29. Osborne CK, Schiff R: Estrogen-receptor biology: Continuing progress and therapeutic implications. J Clin Oncol 23:1616-1622, 2005 (Pubitemid 46211414)
30. Bardou VJ, Arpino G, Elledge RM, et al: Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21:1973- 1979, 2003 (Pubitemid 46606386)
31. McCabe A, Dolled-Filhart M, Camp RL, et al: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808-1815, 2005 (Pubitemid 43033901)
32. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004 (Pubitemid 39627082)
33. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for clinical stage II and III ER+ breast cancer based on treatment response, pathological stage, tumor grade, Ki67 proliferation index, and estrogen receptor status after neoadjuvant endocrine therapy. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 62)